Lupin has entered into an exclusive agreement with Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. The agreement grants Lupin exclusive rights to commercialize and distribute Bofanglutide in India, strengthening Lupin’s diabetes portfolio and presence in the obesity segment. Bofanglutide is intended for treating adults with type 2 diabetes and aiding weight management, potentially offering a convenient alternative to existing weekly treatments.
Partnership for Diabetes Treatment
Lupin Limited has announced an exclusive License, Supply, and Distribution agreement with Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. The collaboration aims to address both diabetes and obesity, providing a potential new treatment option in the Indian market. The announcement was made on December 29, 2025.
Bofanglutide: A Novel Treatment Option
Bofanglutide, developed by Gan & Lee, is designed as a fortnightly (once in two weeks) GLP-1 receptor agonist, targeting adults with type 2 diabetes and overweight or obese individuals. Clinical data suggests weight loss results are comparable to or better than existing alternatives. It also provides a more convenient dosing schedule compared to weekly injectable options.
Addressing Obesity in India
The collaboration comes at a time when obesity is a growing health concern in India, with approximately 174 million adults classified as overweight and around 50 million as obese. The partnership between Lupin and Gan & Lee seeks to provide innovative therapeutic solutions to manage metabolic diseases and combat obesity in India.
Strategic Implications
According to Lupin, this partnership demonstrates the company’s strategic focus on the GLP-1 class of drugs and its commitment to delivering high-quality, innovative therapies. Gan & Lee views the agreement as a significant step in its global strategic advancement, showcasing the value of Chinese biopharmaceutical innovation.
Source: BSE
